$6.99
10.43%
Nasdaq, Apr 21, 08:48 pm CET
ISIN
US77313F1066
Symbol
RCKT
Sector
Industry

Rocket Pharmaceuticals, Inc. Stock price

$6.33
-2.50 28.31% 1M
-12.10 65.65% 6M
-6.24 49.64% YTD
-17.35 73.27% 1Y
-6.79 51.75% 3Y
-9.78 60.71% 5Y
-13.71 68.41% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.18 2.93%
ISIN
US77313F1066
Symbol
RCKT
Sector
Industry

Key metrics

Market capitalization $674.97m
Enterprise Value $328.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.45
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-273.21m
Free Cash Flow (TTM) Free Cash Flow $-215.68m
Cash position $372.34m
EPS (TTM) EPS $-2.73
P/E forward negative
P/S forward 15.34
EV/Sales forward 7.46
Short interest 21.26%
Show more

Is Rocket Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Rocket Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Rocket Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 9.34 9.34
24% 24%
-
-9.34 -9.34
24% 24%
-
- Selling and Administrative Expenses 89 89
40% 40%
-
- Research and Development Expense 165 165
9% 9%
-
-264 -264
5% 5%
-
- Depreciation and Amortization 9.34 9.34
24% 24%
-
EBIT (Operating Income) EBIT -273 -273
5% 5%
-
Net Profit -259 -259
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Rocket Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rocket Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
11 days ago
Rocket Pharmaceuticals' gene therapies offer long-term effects for cardiovascular and hematology diseases, addressing severe unmet needs like Danon Disease, which currently requires heart transplants. The near-term outlook driven by clinical milestones for RP-A601, RP-A501, and potential Kresladi approval, with the current share price at $5 offering significant value. Rocket has $372M in cash, ...
Neutral
Business Wire
18 days ago
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that management will participate in the 24th Annual Needham Virtual Healthcare Conference taking place on April 8, 2025. Gaurav Shah, M.D., Chief Executive...
Neutral
Business Wire
about 2 months ago
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2024. “In 2024, we made strong progress in advancing our gene th...
More Rocket Pharmaceuticals, Inc. News

Company Profile

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

Head office United States
CEO Gaurav Shah
Employees 299
Founded 1999
Website www.rocketpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today